Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
375.58B
Market cap375.58B
Price-Earnings ratio
108.04
Price-Earnings ratio108.04
Dividend yield
2.49%
Dividend yield2.49%
Average volume
8.22M
Average volume8.22M
High today
$154.50
High today$154.50
Low today
$141.80
Low today$141.80
Open price
$146.78
Open price$146.78
Volume
32.54M
Volume32.54M
52 Week high
$154.50
52 Week high$154.50
52 Week low
$77.58
52 Week low$77.58

Stock Snapshot

Merck(MRK) stock is priced at $152.77, giving the company a market capitalization of 375.58B. It carries a P/E multiple of 108.04 and pays a dividend yield of 2.49%.

During the trading session on 2026-08-19, Merck(MRK) shares reached a daily high of $154.50 and a low of $141.80. At a current price of $152.77, the stock is +7.7% higher than the low and still -1.1% under the high.

Trading activity shows a volume of 32.54M, compared to an average daily volume of 8.22M.

The stock's 52-week range extends from a low of $77.58 to a high of $154.50.

The stock's 52-week range extends from a low of $77.58 to a high of $154.50.

MRK News

TipRanks 20m
Merck upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Merck (MRK) to Overweight from Equal Weight with a price target of $179, up from $116. The recent success for Merck pipeline cancer drug...

Zacks 48m
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy? - Zacks Investment Research

...

Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy? - Zacks Investment Research
MarketWatch 1h
Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rally

The stocks of five of the world’s largest drugmakers are on track for a record close. AbbVie’s shares ABBV were up 2.6% on Wednesday, while Amgen AMGN gained 3...

Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rally

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
25.8%
Sell
6.5%

More MRK News

24/7 Wall St. 1h
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? By David Moadel Published Aug 19, 3:20PM EDT Quick Read Merck surged 44% YTD, topping Am...

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
Decrypt 4h
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means

Add Decrypt as your preferred source to see more of our stories on Google. In brief Moderna (MRNA) jumped ~131% Wednesday after the Phase 3 INTerpath-001 trial...

Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
The Motley Fool 4h
Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.

A late-stage trial that combined a messenger ribonucleic acid (mRNA) shot jointly developed by Moderna (MRNA +129.65%) and Merck with Merck’s Keytruda yielded s...

Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.
Nasdaq 5h
From COVID to Cancer: Moderna Scores Melanoma Breakthrough

Moderna, Merck Score Melanoma Cancer Breakthrough Wednesday, Moderna (MRNA) exploded, soaring more than 100% after the company released positive topline result...

From COVID to Cancer: Moderna Scores Melanoma Breakthrough
24/7 Wall St. 5h
Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?

Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold? By Vandita Jadeja Published Aug 19, 12:00PM EDT Quick Read LLY dominates the GLP-1 race with 48% revenue...

Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?
TipRanks 6h
Leerink says cancer vaccine win should sustain Merck momentum into fall

Leerink notes Merck (MRK) and Moderna (MRNA) announced the top-line recurrence-free survival and distant metastasis-free survival success of the Phase 3 INTerpa...

TipRanks 6h
Pfizer Stock Rallies 4% Thanks to Merck and Moderna’s Cancer Trial Update

Pfizer (PFE) stock was up 3.74% on Wednesday, despite a lack of news from the biopharmaceutical company. However, that doesn’t mean that PFE stock was up withou...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.